Jay S. Duker leads EyePoint's execution across business aspects.
3 reports, 2 independent
Updated Aug 17
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jay S. Duker leads EyePoint's execution across business aspects.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jay S. Duker
Nothing else this week.
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Related events
Coverage
Newest first; wire copies grouped- fiercepharma.com
- GlobeNewswireEyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomiz